KR100266799B1 - Nutritional formula for patients with renal disease and process for preparing the same - Google Patents
Nutritional formula for patients with renal disease and process for preparing the same Download PDFInfo
- Publication number
- KR100266799B1 KR100266799B1 KR1020000002937A KR20000002937A KR100266799B1 KR 100266799 B1 KR100266799 B1 KR 100266799B1 KR 1020000002937 A KR1020000002937 A KR 1020000002937A KR 20000002937 A KR20000002937 A KR 20000002937A KR 100266799 B1 KR100266799 B1 KR 100266799B1
- Authority
- KR
- South Korea
- Prior art keywords
- vitamin
- nutritional composition
- kidney disease
- patients
- protein
- Prior art date
Links
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 83
- 208000017169 kidney disease Diseases 0.000 title claims abstract description 58
- 238000004519 manufacturing process Methods 0.000 title abstract description 4
- 239000000203 mixture Substances 0.000 claims abstract description 90
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 32
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 32
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 27
- 239000011707 mineral Substances 0.000 claims abstract description 27
- 235000010755 mineral Nutrition 0.000 claims abstract description 27
- 238000000502 dialysis Methods 0.000 claims abstract description 26
- 229940088594 vitamin Drugs 0.000 claims abstract description 26
- 229930003231 vitamin Natural products 0.000 claims abstract description 26
- 235000013343 vitamin Nutrition 0.000 claims abstract description 26
- 239000011782 vitamin Substances 0.000 claims abstract description 26
- 239000007788 liquid Substances 0.000 claims abstract description 21
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 18
- 235000015097 nutrients Nutrition 0.000 claims abstract description 17
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims abstract description 7
- 235000021281 monounsaturated fatty acids Nutrition 0.000 claims abstract description 6
- 239000000126 substance Substances 0.000 claims abstract description 6
- 235000018102 proteins Nutrition 0.000 claims description 30
- 235000019197 fats Nutrition 0.000 claims description 23
- 108010011756 Milk Proteins Proteins 0.000 claims description 18
- 102000014171 Milk Proteins Human genes 0.000 claims description 18
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 18
- 235000021239 milk protein Nutrition 0.000 claims description 17
- 235000014633 carbohydrates Nutrition 0.000 claims description 16
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 14
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 10
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 229920001353 Dextrin Polymers 0.000 claims description 9
- 239000004375 Dextrin Substances 0.000 claims description 9
- 235000019486 Sunflower oil Nutrition 0.000 claims description 9
- 235000019425 dextrin Nutrition 0.000 claims description 9
- 239000002600 sunflower oil Substances 0.000 claims description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 8
- 239000005018 casein Substances 0.000 claims description 8
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 8
- 235000021240 caseins Nutrition 0.000 claims description 8
- 239000004615 ingredient Substances 0.000 claims description 8
- 239000003531 protein hydrolysate Substances 0.000 claims description 8
- 239000008213 purified water Substances 0.000 claims description 8
- 230000001954 sterilising effect Effects 0.000 claims description 8
- 238000004659 sterilization and disinfection Methods 0.000 claims description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 7
- 235000019739 Dicalciumphosphate Nutrition 0.000 claims description 7
- 239000001506 calcium phosphate Substances 0.000 claims description 7
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 claims description 7
- 229910000390 dicalcium phosphate Inorganic materials 0.000 claims description 7
- 229940038472 dicalcium phosphate Drugs 0.000 claims description 7
- 239000011790 ferrous sulphate Substances 0.000 claims description 7
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 7
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 7
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 7
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 7
- 239000001095 magnesium carbonate Substances 0.000 claims description 7
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 7
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 7
- 239000001508 potassium citrate Substances 0.000 claims description 7
- 229960002635 potassium citrate Drugs 0.000 claims description 7
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 7
- 235000011082 potassium citrates Nutrition 0.000 claims description 7
- 239000011787 zinc oxide Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 5
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 229930003427 Vitamin E Natural products 0.000 claims description 5
- 239000011575 calcium Substances 0.000 claims description 5
- 229960000304 folic acid Drugs 0.000 claims description 5
- 235000019152 folic acid Nutrition 0.000 claims description 5
- 239000011724 folic acid Substances 0.000 claims description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 5
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 5
- 235000019165 vitamin E Nutrition 0.000 claims description 5
- 239000011709 vitamin E Substances 0.000 claims description 5
- 229940046009 vitamin E Drugs 0.000 claims description 5
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- 229960002685 biotin Drugs 0.000 claims description 4
- 235000020958 biotin Nutrition 0.000 claims description 4
- 239000011616 biotin Substances 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims description 4
- 235000005152 nicotinamide Nutrition 0.000 claims description 4
- 239000011570 nicotinamide Substances 0.000 claims description 4
- 229960000342 retinol acetate Drugs 0.000 claims description 4
- 235000019173 retinyl acetate Nutrition 0.000 claims description 4
- 239000011770 retinyl acetate Substances 0.000 claims description 4
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 claims description 4
- 239000001509 sodium citrate Substances 0.000 claims description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 4
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- 229960003975 potassium Drugs 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 239000008158 vegetable oil Substances 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 235000021120 animal protein Nutrition 0.000 claims description 2
- 235000013599 spices Nutrition 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 108010076119 Caseins Proteins 0.000 claims 3
- 102000011632 Caseins Human genes 0.000 claims 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims 1
- 235000020244 animal milk Nutrition 0.000 claims 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- 108010033929 calcium caseinate Proteins 0.000 claims 1
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
- 229940071162 caseinate Drugs 0.000 claims 1
- 230000034659 glycolysis Effects 0.000 claims 1
- 229940057917 medium chain triglycerides Drugs 0.000 claims 1
- 235000019691 monocalcium phosphate Nutrition 0.000 claims 1
- 229940014662 pantothenate Drugs 0.000 claims 1
- 235000019161 pantothenic acid Nutrition 0.000 claims 1
- 239000011713 pantothenic acid Substances 0.000 claims 1
- 229940080237 sodium caseinate Drugs 0.000 claims 1
- 230000035764 nutrition Effects 0.000 abstract description 21
- 235000005911 diet Nutrition 0.000 abstract description 12
- 230000006870 function Effects 0.000 abstract description 8
- 230000037213 diet Effects 0.000 abstract description 7
- 230000029142 excretion Effects 0.000 abstract description 6
- 230000001684 chronic effect Effects 0.000 abstract description 4
- 230000001154 acute effect Effects 0.000 abstract description 3
- 238000001631 haemodialysis Methods 0.000 abstract description 3
- 230000000322 hemodialysis Effects 0.000 abstract description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract description 2
- 208000001647 Renal Insufficiency Diseases 0.000 abstract description 2
- 238000001914 filtration Methods 0.000 abstract description 2
- 201000006370 kidney failure Diseases 0.000 abstract description 2
- 239000008101 lactose Substances 0.000 abstract description 2
- 235000000053 special nutrition Nutrition 0.000 abstract description 2
- 241001494479 Pecora Species 0.000 abstract 1
- 239000003925 fat Substances 0.000 description 21
- 239000011812 mixed powder Substances 0.000 description 21
- 210000003734 kidney Anatomy 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- -1 glycerin fatty acid Chemical class 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 230000007935 neutral effect Effects 0.000 description 7
- 208000020832 chronic kidney disease Diseases 0.000 description 6
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 6
- 235000019796 monopotassium phosphate Nutrition 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 6
- 230000000378 dietary effect Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000009304 Acute Kidney Injury Diseases 0.000 description 4
- 208000033626 Renal failure acute Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 201000011040 acute kidney failure Diseases 0.000 description 4
- 208000012998 acute renal failure Diseases 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 4
- 229960002079 calcium pantothenate Drugs 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000035622 drinking Effects 0.000 description 4
- 235000020776 essential amino acid Nutrition 0.000 description 4
- 239000003797 essential amino acid Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 235000003715 nutritional status Nutrition 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 208000037157 Azotemia Diseases 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 230000006371 metabolic abnormality Effects 0.000 description 3
- 208000015380 nutritional deficiency disease Diseases 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229940045136 urea Drugs 0.000 description 3
- 208000009852 uremia Diseases 0.000 description 3
- 229940116269 uric acid Drugs 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940085912 calcium carbonate 200 mg Drugs 0.000 description 2
- 229940085869 calcium carbonate 300 mg Drugs 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 238000011903 nutritional therapy Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- CIVAZQNUIZWSLB-UFLZEWODSA-N C(C1=CN=CC=C1)(=O)N.OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12 Chemical compound C(C1=CN=CC=C1)(=O)N.OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12 CIVAZQNUIZWSLB-UFLZEWODSA-N 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 101000937129 Drosophila melanogaster Cadherin-related tumor suppressor Proteins 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000002682 Hyperkalemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- FAJBDLZKHQSYBV-UHFFFAOYSA-H [Fe+2].[Mg+2].P(=O)([O-])([O-])[O-].[Ca+2].P(=O)([O-])([O-])[O-] Chemical compound [Fe+2].[Mg+2].P(=O)([O-])([O-])[O-].[Ca+2].P(=O)([O-])([O-])[O-] FAJBDLZKHQSYBV-UHFFFAOYSA-H 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 230000037208 balanced nutrition Effects 0.000 description 1
- 235000019046 balanced nutrition Nutrition 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 235000021310 complex sugar Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000005188 flotation Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 210000002758 humerus Anatomy 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 201000005991 hyperphosphatemia Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- MVFCKEFYUDZOCX-UHFFFAOYSA-N iron(2+);dinitrate Chemical compound [Fe+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O MVFCKEFYUDZOCX-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 235000021542 oral nutrition Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000009116 palliative therapy Methods 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 201000006409 renal osteodystrophy Diseases 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000021023 sodium intake Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
Abstract
본 발명은 신장병 환자를 위한 영양조성물에 관한 것이다. 좀 더 구체적으로, 본 발명은 급성 또는 만성으로 신장의 여과 및 배설기능이 약화된 비투석 신장병 환자나 신부전의 진행으로 혈액투석이 요구되는 투석 신장병 환자 등에게 간편하고 안전하게 충분한 영양을 공급할 수 있는 액상의 영양조성물 및 그의 제조방법에 관한 것이다. 본 발명의 양양 조성물은 100g당 총 200㎉의 열량을 가지며, 3대 영양소(단백질, 지방, 탄수화물)의 열량비율이 단백질 4 내지 14 중량 %, 지방 22.5 내지 31.5 중량 % 및 탄수화물 62 내지 74 중량 %이고, 비타민류와 무기질류는 한국인 성인 1일 권장량의 5 내지 15 중량 %를 함유한 영양균형 특수영양식품으로서, 단순불포와지방산에 대한 다가불포화지방산의 비율(P/M)이 1이하이고, 유당을 함유하지 않는다. 본 발명의 신장병 환자용 액상 영양조성물은 기존의 병원이나 가정에서 이루어지던 신장병 환자용 식이에 비하여, 보다 간편하고 효과적으로 신장병 환자에게 양양을 공급할 수 있는 새로운 영양물질로 사용될 수 있다.The present invention relates to a nutritional composition for kidney disease patients. More specifically, the present invention is a liquid or liquid that can easily and safely provide sufficient nutrition to patients with non-dialysis nephropathy who have acute or chronic weakened filtration and excretion functions or dialysis nephropathy patients who require hemodialysis due to renal failure. It relates to a nutritional composition of and a method for producing the same. The foster composition of the present invention has a total calorific value of 200 kcal per 100 g, the caloric ratio of the three major nutrients (protein, fat, carbohydrate) is 4 to 14% by weight protein, 22.5 to 31.5% fat and 62 to 74% carbohydrate Vitamins and minerals are nutritionally balanced special nutrition products containing 5 to 15% by weight of the daily recommended amount of Korean adults, the ratio of polyunsaturated fatty acid (P / M) to monounsaturated fatty acid is less than 1, Contains no lactose Liquid nutritional composition for kidney disease patients of the present invention can be used as a new nutritional substance that can provide a sheep to the kidney disease patients more simply and effectively than the diet for kidney disease patients made in the existing hospital or home.
Description
본 발명은 신장병 환자를 위한 영양조성물에 관한 것이다. 좀 더 구체적으로, 본 발명은 급성 또는 만성으로 신장의 여과 및 배설기능이 약화된 비투석 신장병 환자나 신부전의 진행으로 혈액투석이 요구되는 투석 신장병 환자 등에게 간편하고 안전하게 충분한 영양을 공급할 수 있는 액상의 영양조성물 및 그의 제조방법에 관한 것이다.The present invention relates to a nutritional composition for kidney disease patients. More specifically, the present invention is a liquid or liquid that can easily and safely provide sufficient nutrition to patients with non-dialysis nephropathy who have acute or chronic weakened filtration and excretion functions or dialysis nephropathy patients who require hemodialysis due to renal failure. It relates to a nutritional composition of and a method for producing the same.
우리의 신체에서 신장은 횡경막 아래 척추의 양측에 1쌍이 있는데, 지방피막에 싸여 복막과 후복벽의 사이에 위치한다. 성인에서 한쪽 신장의 무게는 130~170g이며, 크기는 성인의 주먹만하다. 한쪽 신장에는 약 100만개 정도의 시장기능의 기본단위인 네프론이 존재하는데. 이 기관은 모세혈관 덩어리인 사구체와 이에 연결된 가늘고 긴 세뇨관으로 구성되어 있다.In our body, there is a pair of kidneys on either side of the spine below the diaphragm, wrapped in a fat envelope, between the peritoneum and the posterior wall. One adult weighs 130-170 grams, the size of an adult's fist. One kidney contains about 1 million units of nephron, the basic unit of market function. It consists of glomeruli, capillary masses, and elongated tubules connected to it.
신장의 주된 기능은 체내에서 일어나는 여러가지 음식물의 대사과정에서 유래되는 노폐물과 체내로 들어온 이물질 등을 소변을 통해 체외로 배설하는 것이며, 이외에도 체액조절기능, 혈압유지, 적혈구 수 조절 및 성장인자 합성 등의 많은 기능을 수행한다.The main function of the kidney is to excrete waste products from the metabolism of various foods in the body and foreign substances that enter the body through urine.In addition, it regulates body fluids, maintains blood pressure, regulates the number of red blood cells and synthesizes growth factors. It performs many functions.
이와 같이 신장은 배설, 조절 및 내분비 기관으로서의 역할을 수행하므로, 신장의 기능이 저하되면 혈액 중의 노폐물(요소, 요산, 크레아티닌, 황산염, 및 유기산)의 양이 증가하고, 체내 수분 및 전해질의 배설 장애로 균형을 잃게 된다. 이 질환으로 인한 증상으로는, 식욕부진, 피로감, 구토증 및 두통 등의 만성증상과 부종, 혈압상승 등의 중증의 증상들이 동반되며, 질병이 악화되는 경우에는 요독증으로 생명을 잃게 된다.Thus, the kidney plays a role in excretion, regulation and endocrine organs, so when the function of the kidney is reduced, the amount of waste products (urea, uric acid, creatinine, sulfate, and organic acid) in the blood increases, and the body's water and electrolyte excretion disorders Will lose balance. Symptoms of this disease include anorexia, fatigue, nausea and headache, chronic symptoms such as swelling, severe symptoms such as increased blood pressure, and when the disease worsens, the life of uremia.
신장질환의 치료방법으로는, (1) 유지 또는 고식적 요법(conservative treatment), (2) 혈액투석(hemodialysis), (3) 복막투석(peritoneal dialysis) 또는 (4) 신장이식(renal transplantation) 등이 있는데, 각각의 치료방법에 따라 영양공급의 기준이 달라진다.Treatments for kidney disease include (1) maintenance or conservative treatment, (2) hemodialysis, (3) peritoneal dialysis, or (4) renal transplantation. There is a different standard of nutrition for each treatment.
신장질환에서는 많은 대사이상과 환자의 쇠약(衰弱)이 발생하기 쉽기 때문에, 영양요법(nutrition therapy)은 신장병 치료에서 대단히 중요한 일면을 차지하고 있다. 특히, 신장질환시에는 양양소의 대사이상 또는 대사산물에 의한 이상이 많이 발생하는데, 예를 들면, 이들 이상에는 요소, 요산, 및 크레아티닌 등의 단백질 대사산물과 나트륨(Na), 칼륨(K) 및 인(P) 등의 신장배설기능이 감소되고, 칼슘(Ca), 철(Fe)과 같은 무기질의 장관흡수도 감소된다. 또한, 신장질환 환자는 쇠약하거나, 영양불량인 경우가 빈번한데, 그 이유는 다음과 같다:In kidney disease, many metabolic disorders and weakness of the patient are likely to occur, so nutrition therapy is an important aspect in treating kidney disease. In particular, during kidney disease, metabolic abnormalities or metabolic abnormalities of nutrients are generated. For example, these abnormalities include protein metabolites such as urea, uric acid, and creatinine, and sodium (Na), potassium (K), and Kidney excretion, such as phosphorus (P) is reduced, and the intestinal absorption of minerals such as calcium (Ca), iron (Fe) is also reduced. In addition, kidney disease patients are often weak or malnourished, for the following reasons:
첫째, 만성소모성질환(chronic debilitating illness), 요독증 및 감정적 의기소침 등에 의해 발생되는 식욕부진(anorexia)으로 인하여, 식사섭취량이 불충분하게 되어 필요한 열량이 부족하다;First, due to anorexia caused by chronic debilitating illness, uremia, and emotional depression, the intake of meals is insufficient, resulting in insufficient calories;
둘째, 심한 이화장애(catabolic illness)가 합병된다;Second, severe catabolic illness is merged;
셋째, 검사를 위한 채혈과 잠혈성 위장출혈 등으로 인하여 체내 단백질이 결핍된다;Third, there is a deficiency of protein in the body due to blood sampling and occult gastrointestinal bleeding;
넷째, 아미노산, 단백질, 포도당 및 수용성비타민 등의 생물활성물질의 손실이 일어난다.Fourth, bioactive substances such as amino acids, proteins, glucose and water-soluble vitamins are lost.
상기와 같은 신장질환자의 대사장애, 쇠약 및 양양불량을 개선하기 위한 영양치료의 노력은 20세기 초반부터 체계적으로 시도되어, 고생물가의 단백질 식품과 전분 제품으로 신장질환 환자의 에너지 섭취를 권장한 예를 지오바네티(Giovannetti, S) 등이 보고하였다(참조: Giovannetti, S. et al., Lancet, 1:1000(1964)). 한편, 올드리찌(Oldrizzi, L.) 등은 급ㆍ만성신부전 환자의 치료에서 영양관리는 가장 중요한 요인이며, 섭취하는 질소원의 양과 질을 제한함으로써 신장질환의 악화를 지연시킬 수 있다고 보고하였는데(참조: L. Oldrizzi, et al., Nutritional in Clinical Practice, 9:1(1994)), 그 내용을 요약하면 다음과 같다.Efforts to improve the metabolic disorders, weakness, and malnutrition of kidney diseases have been attempted systematically since the beginning of the 20th century. For example, high-protein protein foods and starch products are recommended for energy intake of kidney disease patients. Giovannetti (S) et al. Reported by Giovannetti, S. et al., Lancet, 1: 1000 (1964). On the other hand, Oldrizzi (L.) and others reported that nutrition management is the most important factor in the treatment of patients with acute and chronic renal failure, and may delay the exacerbation of kidney disease by limiting the amount and quality of the nitrogen source ingested. : L. Oldrizzi, et al., Nutritional in Clinical Practice, 9: 1 (1994)).
ㆍ만성신부전의 영양관리ㆍ Nutrition management for chronic renal failure
만성신부전의 식이관리는 1960년대 유지요법(또는 고식적요법)으로부터 시작되어, 현재에는 단백질과 인의 제한이 가장 보편적인 식이관리 조건이 되었다. 또한, 지질의 대사이상으로 인한 만성신부전이 요독증(uremia)으로 진전될 수 있으므로, 적절한 양과 질의 지방 공급이 필요하다. 올드리찌 등이 제안한 만성신부전의 일반적인 식이관리 기준은 다음과 같다: (1) 질소원의 섭취 제한과 체내 질소균형 유지를 위해 고생물가의 단백질이 권장된다; (2) 필수아미노산 요구량을 충족시킬 수 있는 단백질 섭취가 권장된다; (3) 체단백질 손실 감소를 위한 충분한 에너지 공급이 권장된다; (4)식이는 맛이 있고 경제적이어야 한다.Dietary management of chronic kidney failure began with maintenance therapy (or palliative therapy) in the 1960s, and protein and phosphorus restriction are now the most common dietary management conditions. In addition, chronic renal failure due to metabolic abnormalities of lipids may progress to uremia, so proper amount and quality of fat supply is necessary. The general dietary management criteria for chronic renal failure proposed by Aldrich et al. Include: (1) High-protein proteins are recommended to limit the intake of nitrogen sources and to maintain nitrogen balance in the body; (2) protein intake that meets essential amino acid requirements is recommended; (3) sufficient energy supply to reduce body protein loss is recommended; (4) The diet should be tasty and economic.
ㆍ급성신부전의 영양관리ㆍ Nutrition management for acute renal failure
급성신부전의 영양관리는 만성신부전의 영양관리보다 좀더 엄격한 식이 제한이 필요하며, 그 내용은 다음과 같다: (1) 적절한 에너지(열량) 섭취는 요소합성과 단백질 이화를 억제시키는 역할을 하기 때문에, 급성신부전 환자의 영양치료의 핵심이 되며, 에너지 공급은 환자에 따라 1,500~2,700㎉/日가 권장된다; (2) 아미노산은 필수아미노산과 비필수아미노산의 혼합사용이 권장되고, 경구섭취가 가능한 경우 체중 ㎏당 0.6g/日이 권장된다/ (3) 지방은 섭취 총열량의 10~20% 정도의 구성이 요구되어, 1일 400㎉(45(g)정도가 권장된다; (4) 수용성 비타민의 요구량이 증가된다; (5) 무기질의 경우, 칼륨(K), 인(P) 등이 제한된다.Nutritional management of acute renal failure requires dietary restrictions that are more stringent than nutritional management of chronic renal failure, including: (1) Since adequate energy intake plays a role in inhibiting urea synthesis and protein catabolism, It is the core of nutritional therapy for patients with acute renal failure, and energy supply of 1,500 ~ 2,700㎉ / day is recommended depending on the patient; (2) It is recommended to use a mixture of essential amino acid and non-essential amino acid, and 0.6g / day per kg of body weight is recommended if oral ingestion is possible. It is recommended that about 400 ㎉ (45 g) per day is recommended; (4) the required amount of water-soluble vitamins is increased;
결국 신장질환의 영양관리 목표는 다음과 같다:Ultimately, nutritional management goals for kidney disease are:
첫째, 질소분해산물의 과량축적을 방지하고, 양성 질소평형(positive nitrogen balance)을 유지하기 위해 아미노산 조성 및 생물가가 높은 단백질을 공급한다;First, to provide protein with high amino acid composition and high biovalence to prevent excessive accumulation of nitric acid products and to maintain a positive nitrogen balance;
둘째, 체단백질의 손실을 방지하기 위해 충분한 열량을 섭취한다;Second, they consume enough calories to prevent loss of body protein;
셋째, 혈압 조절과 갈증 및 부종을 방지하기 위해 나트륨 섭취를 제한한다.Third, limit sodium intake to control blood pressure and prevent thirst and edema.
넷째, 고칼륨혈증과 체중증가를 방지하기 위해 수분 섭취를 제한한다;Fourth, limit water intake to prevent hyperkalemia and weight gain;
다섯째, 고인산혈증 및 신성골이영양증(renal osteodystrophy)을 방지하기 위해 인의 섭취를 제한한다.Fifth, limit the intake of phosphorus to prevent hyperphosphatemia and renal osteodystrophy.
신장질환자는 이상과 같은 영양기준과 영양치료를 충족시킴으로써 질환을 개선시키거나 악화를 지연시키고, 육체적ㆍ심리적 안정을 유지하여 삶의 질을 유지 시킬 수 있다. 그러나, 신장질환자도 기타의 질환자와 마찬가지로 다양한 음식섭취가 불가능하고 소화능력이 저하되어 있으므로, 가능한 한 1일 필요영양소가 균형있게 섭취될 수 있는 식품이 요구됨과 동시에, 신장의 질환에 따른 영양소의 가감 및 구성성분의 적절한 선택이 필요하다. 이러한 점에서, 신장질환자를 위한 병원 및 가정에서의 식이 조제는 제반 영양학적 기준에 부적합한 채로 환자에게 사용되었던 바, 필연적으로 영양학적 불균형을 초래하였으며, 특히 다음과 같은 제반 문제점이 지적되어 왔다:Kidney patients can meet the above nutritional standards and nutritional therapies to improve or delay disease, maintain physical and psychological stability and maintain quality of life. However, like other diseases, kidney disease is impossible to eat a variety of foods, and digestive capacity is reduced, so as to be able to eat a balanced diet of necessary nutrients as much as possible daily, and at the same time the addition of nutrients according to kidney disease And proper selection of components. In this regard, dietary preparations in hospitals and homes for kidney disease have been used in patients with inadequate nutritional standards, which inevitably lead to nutritional imbalances, in particular the following problems:
첫째, 환자식 제조시 세균에 오염되기 쉽다;First, it is susceptible to bacterial contamination in the manufacture of patient foods;
둘째, 사용하는 재료에 따라 영양성분 조성의 차이가 있다;Second, there are differences in nutritional composition depending on the ingredients used;
셋째, 완전히 액화되지 않거나 불용성 성분으로 인하여 관을 통한 급식이 어렵다;Third, feeding through the tube is difficult due to incomplete liquefaction or insoluble components;
넷째, 별도의 공간이 필요하고, 조제를 위한 시간과 노력이 많이든다;Fourth, extra space is required, and time and effort for preparation are high;
다섯째, 정확하고 균일한 열량 및 영양소 공급이 어렵다;Fifth, it is difficult to supply accurate and uniform calories and nutrients;
여섯째, 식재료비 및 간접비용으로 인하여 원가부담이 상승된다;Sixth, cost burden increases due to food and overhead costs;
일곱째, 침전이 발생하거나, 유화가 이루어지지 않아 기름성분이 분리되는 품절 저하로 인하여 관급식이 어렵다.Seventh, the sedimentation or emulsification is not made due to the out of stock deterioration of the oil component is difficult to feed.
결국, 이러한 종래 식재료에 함유되어 있는 성분이 신장질환자의 영양요구량에 맞지 않는 문제점과 침전, 응고 및 부유 등 제품 안정성의 많은 문제점으로 인하여, 신장질환자를 위한 적절한 영양조성물이 개발되지 못하였다. 따라서, 신장질환자에게 효과적으로 양양을 공급할 수 있도록 영양학적 균형과 제품의 안전성에 개선된 영양조성물을 개발하여야 할 필요성이 절실히 요구되어 왔다.As a result, due to the problems that the ingredients contained in the conventional ingredients do not meet the nutritional requirements of the kidney disease, and many problems of product stability, such as precipitation, coagulation and flotation, an appropriate nutritional composition for the kidney disease was not developed. Therefore, there is an urgent need to develop a nutritional composition that is improved in nutritional balance and product safety in order to effectively provide nutrition to kidney disease patients.
이에, 본 발명자들은 이러한 제반 문제점을 해결하고, 영양학적 균형과 제품의 안정성이 개선되어 양양소의 섭취가 엄격히 제한되는 신장병 질환자들에게 효과적으로 영양을 공급할 수 있는 영양조성물을 개발하고자 예의 연구노력한 결과, 단백질, 지방, 탄수화물과 비타민 및 무기질류를 적절히 함유하는 액상 영양조성물이 신장질환자에게 효과적으로 영양을 공급하여 이들의 여러가지 신체지수가 증가함을 확인하고, 본 발명을 완성하게 되었다.Therefore, the present inventors have solved these problems and improved the nutritional balance and stability of the product, and as a result of intensive research to develop a nutritional composition that can effectively provide nutrition for kidney disease patients whose nutrient intake is strictly restricted, Liquid nutrient composition containing appropriate fats, carbohydrates and vitamins and minerals effectively supply nutrients to the kidney disease to confirm that their various body index increases, and completed the present invention.
결국, 본 발명의 목적은 신장병 환자들에게 적합한 영양조성물을 제공하는 것이다.After all, it is an object of the present invention to provide a nutritional composition suitable for patients with kidney disease.
본 발명의 다른 목적은 전기 신장병 환자를 위한 영양조성물의 제조방법을 제공하는 것이다.It is another object of the present invention to provide a method of preparing a nutritional composition for an electric kidney patient.
단백질의 주된 영양학적 기능은 필수 아미노산과 체조직 단백질의 합성이며, 그 필요량은 '신체적 활동을 적당한 수준으로 할 때의 에너지 균형을 유지하며 체내 질소배설량과 식이질소 섭취량이 균형을 이루는 최소의 수준'이라고 정의되고 있다(참조: WHO, 1985). 단백질은 체내에서 대사될 때, 여러가지 질소분해산물(요소, 크레아티닌, 요산)을 생성하는데, 이들은 신장을 통하여 배설되므로 신장의 기능이 저하된 신장질환자에게는 부담이 될 수 있으며, 이러한 이유로 단백질의 섭취가 제한되고 있다. 이에, 본 발명자들은 단백질의 영양지표인 생물가(biological value)와 단백가(protein score)가 높은 것으로 알려져 있는 분리유단백 또는 가수분물을 사용하면, 단백질의 분해시 신장에 주는 부담을 줄일 수 있을 것으로 예상하였다.The main nutritional function of proteins is the synthesis of essential amino acids and body tissue proteins, and the required amount is 'the minimum level that balances the amount of nitrogen excretion and dietary nitrogen intake in the body while maintaining the energy balance when the physical activity is at an appropriate level'. Defined (WHO, 1985). When proteins are metabolized in the body, they produce a variety of nitric acid products (urea, creatinine, and uric acid), which are excreted through the kidneys, which can be a burden for kidney patients with reduced kidney function. It is becoming. Therefore, the present inventors expected to reduce the burden on the kidneys when the protein is broken down by using protein or hydrolysates, which are known to have high biological scores and protein scores. .
한편, 지방은 영양소들 중 가장 높은 열량(9㎉/g)을 함유하고 있고, 필수 지방산의 공급과 체내 지용성 비타민의 소화 흡수를 도와주며, 체구성 성분으로서의 기능, 생체기관 보호기능 및 식품의 향미와 미각을 증가시키는 기능이 있다. 신장질환자의 식이에서는 단백질이 제한되므로, 지방과 탄수화물로 필요한 열량을 보충하게 되어 식이 중 이들의 함량이 높아진다. 그런나, 신장질환자의 경우, 여러가지 원인으로 인하여 고지혈증이 일어나는 것으로 알려져 있어, 식이 중 지방원의 선택이 매우 중요하다. 이에, 본 발명자들은 고지혈증 환자에서 저밀도지단백 콜레스테롤과 총 콜레스테롤의 함량을 낮추고, 고밀도지단백 콜레스테롤의 상대적 함량을 높이기 위하여, 단일불포화 지방산(monounsaturated fatty acid, 이하 'M' 이라 약함)과 다가불포화 지방산(polyunsaturated fatty acid, 이하 'P'라 약함)이 풍부한 것으로 알려져 있는 해바라기유를 사용함으로써, 고지방 식이에서 올 수 있는 부작용을 줄이고자 하였다. 또한, 소화ㆍ흡수가 용이한 중쇄중성지방(MCT oil)을 사용함으로써 지방흡수 불량 환자에게도 사용할 수 있도록 하였다.On the other hand, fat contains the highest calorie value (9㎉ / g) among the nutrients, and it supports the supply of essential fatty acids and digestion and absorption of fat-soluble vitamins in the body, functions as a body composition, biological organ protection and food flavor And the ability to increase taste. In the diet of the kidney disease, the protein is limited, so the fat and carbohydrates to supplement the necessary calories are high in their diet. However, in the case of kidney disease, hyperlipidemia is known to occur due to various causes, so it is very important to select a fat source in the diet. Accordingly, the present inventors have suggested that monounsaturated fatty acid (weakly referred to as 'M') and polyunsaturated fatty acid (polyunsaturated fatty acid) in order to lower the contents of low density lipoprotein cholesterol and total cholesterol and increase the relative content of high density lipoprotein cholesterol in hyperlipidemia patients. The use of sunflower oil, which is known to be rich in fatty acids (hereinafter referred to as 'P'), aims to reduce the side effects of high-fat diets. In addition, the use of heavy chain triglycerides (MCT oil), which is easy to digest and absorb, can be used in patients with poor fat absorption.
또한, 탄수화물은 저단백, 고칼로리의 식사요법이 요구되는 신장질환자에게 칼로리 원으로 중요한 위치를 차지한다. 그러나, 탄수화물은 소화 흡수시, 단당류 또는 이당류로 분해되어 감미가 높아져 대량의 섭취가 곤란하거나, 급격한 혈당의 상승을 초래하여 당뇨병 등의 증세를 악화시킬 수 있다. 따라서, 소화흡수 속도가 느리면서 에너지원이 될 수 있는 복합당질의 섭취가 권장되는 바, 본 발명자들은 감미와 소화흡수 속도 등을 감안하여 덱스트린을 본 발명의 영양조성물에 사용하였다.In addition, carbohydrates occupy an important position as a calorie source for kidney disease patients requiring low protein, high calorie diet. However, carbohydrates, when digested and absorbed, may be broken down into monosaccharides or disaccharides to increase sweetness, making it difficult to consume large quantities, or may cause rapid blood sugar rise, which may worsen symptoms such as diabetes. Therefore, the ingestion of a complex sugar that can be a source of energy while slowing the absorption of digestion is recommended, the present inventors used dextrin in the nutritional composition of the present invention in consideration of sweetness and digestion absorption rate.
본 발명자들은 우선 영양조성물의 용도를 비투석 신장병 환자용과 투석 신장병 환자용으로 구분한 다음, 상술한 바와 같은 선택 원리에 의하여 단백질, 지방 및 탄수화물을 각각에 적합한 조성 및 성분비로 함유하고, 미량의 비타민 및 무기 질류를 함유하는 영양조성물을 제조하였다. 즉, 단백질원으로 분리유단백 또는 분리유단백 가수분해물을 포함하고; 단순불포화지방산에 대한 다가불포화지방산의 비율(P/M)이 1 이하가 되도록 불포화지방산을 포함하며; 탄수화물원으로서 복합당질을 포함하고; 신장질환자가 일일 필요한 정도에 따라 비타민 및 무기질류를 포함하는 액상 영양조성물을 혼합 및 균질시킨 다음, 고온멸균 처리하여, 신장병 환자용 영양조성물을 제조하였다. 이들 영양조성물들은 대부분의 신장질환자에게 권장되는 열량인 2,000㎉를 섭취하였을 때, 균형있는 영양공급이 이루어지도록 제조되었으며, 단백질에 의하여 공급디는 열량을 신장질환자에 적합한 수준으로 제한한 것을 특징으로 하고 있다. 특히, 투석 신장질환자용 영양조성물의 경우, 투석으로 인한 단백질의 손실을 고려하여 비투석 환자에 비하여 높은 단백질 함량을 가지도록 제조되었다. 또한, 지방과 탄수화물은 생리적으로 우수한 원료를 선태하여, 상술한 바와 같은 여러가지 부작용을 최소화하고자 하였다.The present inventors first divide the use of nutritional composition for patients with dialysis kidney disease and patients with dialysis kidney disease, and then, according to the selection principle as described above, contain protein, fat, and carbohydrate in appropriate composition and composition ratio, respectively, A nutrition composition containing inorganic matters was prepared. That is, the protein source comprises a separated milk protein or a separated milk protein hydrolyzate; Unsaturated fatty acids so that the ratio (P / M) of polyunsaturated fatty acids to monounsaturated fatty acids is 1 or less; A complex carbohydrate as a carbohydrate source; Kidney patients mixed and homogenized liquid nutritional composition containing vitamins and minerals according to the daily needs, and then subjected to high temperature sterilization, to prepare a nutritional composition for kidney disease patients. These nutrients are formulated to provide balanced nutrition when intake of 2,000 ㎉ calories, which is recommended for most kidney disease, and is characterized by limiting the amount of calories supplied by protein to a level suitable for kidney disease. have. In particular, in the case of the nutritional composition for dialysis kidney disease, it was prepared to have a higher protein content than non-dialysis patients in consideration of the loss of protein due to dialysis. In addition, fats and carbohydrates were selected as physiologically superior raw materials, to minimize various side effects as described above.
이하에서는, 본 발명의 신장병 환자용 영양조성물의 제조방법을 보다 구체적으로 설명하고자 한다.Hereinafter, a method of preparing the nutritional composition for a kidney disease patient of the present invention will be described in more detail.
하기 표 1은 본 발명의 비투석 및 투석 신장질환자용 액상 영양조성물을 제조하기 위한 각 영양성분 물질의 첨가량을 표로 나타낸 것이다.Table 1 below shows the amounts of each nutrient substance for preparing a liquid nutritional composition for dialysis and dialysis kidney disease patients of the present invention.
본 발명의 신장병 환자용 액상영양조성물은 상기 표 1에서 보여지는 바와 같이, 단백질원으로서 단백질 함량이 90% 이상인 카제인류 분리유단백(카제인, 카제인나트륨, 카제인칼륨, 카제인칼슘) 또는 카제인류 분리유단백 가수분해물(아미노산 3 내지 5개의 결합체) 등의 동물성 단백질을 제품의 특성에 따라 100g당 2 내지 7 중량 %를 함유하도록 물에 용해시킨 다음, 지방원으로서 다가불포화지방산(P)과 단순불포화지방산(M)의 비율이 1 이하인 해바라기유 또는 중쇄중성지방 등의 식물성 유지를 5 내지 7 중량 %, 탄수화물원으로서 당분해도(dextrose equivalent, DE) 값이 10 내지 19 사이인 덱스트린과 정백당을 혼합(혼합비율은 중량비로 24:1 내지 25:1)하여 31 내지 37 중량 %, 비타민과 무기질류를 한국인 성인 1일 권장량을 기준으로 신장질환자가 일일 필요한 정도에 따라 미량 혼합하고, 글리세린 지방산에 스테르 등의 유화제 0.3 내지 0.5 중량 % 및 요구르트향, 땅콩향, 바닐라향, 밀크향, 커피향, 밤향 등의 향료 0.2 내지 0.4 중량 %를 함유하도록 분산시킨다. 이어, 150㎏/㎠의 내지 450㎏/㎠의 압력조건으로 균질화시키고, 충진온도 80℃ 내지 95℃에서 충진시킨 다음, 121℃ 내지 140℃에서 30초 내지 15분 동안 고온 멸균처리하여 제조한다.Liquid nutrient composition for patients with kidney disease of the present invention, as shown in Table 1, a casein separated milk protein (casein, casein sodium, casein potassium, casein calcium) or casein isolate milk protein hydrolyzate having a protein content of 90% or more as a protein source Animal proteins such as (3-5 amino acids) (dissolved in amino acids) are dissolved in water so as to contain 2 to 7% by weight, based on the characteristics of the product, and then polyunsaturated fatty acids (P) and monounsaturated fatty acids (M) as fat sources. 5 to 7% by weight of vegetable oils such as sunflower oil or heavy chain neutral fat having a ratio of 1 or less, and dextrin and white sugar having a dexrose equivalent (DE) value of 10 to 19 as a carbohydrate source (mixing ratio is weight ratio 24: 1 to 25: 1) to 31 to 37% by weight, the amount of vitamins and minerals required by Korean adults daily The mixture is mixed in a small amount, and dispersed in a glycerin fatty acid so as to contain 0.3 to 0.5% by weight of emulsifiers such as steter and 0.2 to 0.4% by weight of flavors such as yogurt, peanut, vanilla, milk, coffee, chestnut and the like. Subsequently, the mixture is homogenized under a pressure condition of 150 kg / cm 2 to 450 kg / cm 2, and filled at a filling temperature of 80 ° C. to 95 ° C., followed by high temperature sterilization at 121 ° C. to 140 ° C. for 30 seconds to 15 minutes.
이와 같이 제조된 본 발명의 액상 영양조성물 중에 함유되어 있는 각 영양성분의 순수한 함량 및 한국인 영양권장량은 하기 표 2와 같다.The pure content of each nutrient contained in the liquid nutrient composition of the present invention prepared as described above and the recommended amount of Korean nutrition are shown in Table 2 below.
*참고문헌: 한국인 영양권장량 제 6차 개정(1995), 한국영양학회* Reference: Sixth Amendment (1995), The Korean Nutrition Society
한편, 전술한 바와 같이 제조된 본 발명의 영양조성물은, 하기 표 3과 같은 물성을 가지며, 15 내지 25℃의 상온에서 1년간 보관하여도 지방분리 및 단백질 침전이 일어나지 않았다.On the other hand, the nutritional composition of the present invention prepared as described above, has the physical properties as shown in Table 3 below, even if stored for 1 year at room temperature of 15 to 25 ℃ did not occur fat separation and protein precipitation.
이하, 실시예에 의하여 본 발명을 더울 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 국한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in detail with reference to Examples. These examples are only for illustrating the present invention in more detail, and it will be apparent to those skilled in the art that the scope of the present invention is not limited to these examples according to the gist of the present invention.
실시예 1;Example 1;
분리유단백 또는 분리유단백 가수분해물 2.2g, 해바라기유 3.4g, 중쇄중성지방 1.3g, 글리세린 지방산에스테르 0.3g 및 하기 표 4의 무기질 혼합분말 0.3877g을 정제수 40.6052g에 균일하게 혼합 분산시키고, 150㎏/㎠ 내지 450㎏/㎠의 고압으로 균질화하였다. 여기에, 덱스트린 49.6g, 정백당 2.0g, 하기 표 5의 비타민 혼합분말 0.0071g 및 향로 0.2g을 가하여 전체중량을 100g으로 한 다음, 10 내지 20분간 재차 혼합하였다. 이어, 80℃ 내지 95℃의 온도로 충진한 다음, 121℃ 내지 140℃에서 30초 내지 15분간 고온 멸균처리하여 액상의 영양조성물을 제조하였다.2.2 g of the separated milk protein or separated milk protein hydrolyzate, 3.4 g of sunflower oil, 1.3 g of medium chain neutral fat, 0.3 g of glycerin fatty acid ester and 0.3877 g of the inorganic mixed powder of Table 4 were uniformly mixed and dispersed in 40.6052 g of purified water, and 150 kg / Homogenized at a high pressure of 2 cm 2 to 450 kg / cm 2. To this, 49.6 g of dextrin, 2.0 g of per white sugar, 0.0071 g of vitamin mixed powder of Table 5 and 0.2 g of incense were added to make the total weight 100 g, and then mixed again for 10 to 20 minutes. Subsequently, the mixture was filled at a temperature of 80 ° C. to 95 ° C., followed by high temperature sterilization at 121 ° C. to 140 ° C. for 30 seconds to 15 minutes, thereby preparing a liquid nutrition composition.
*함량조성: 한국인 권장량의 5%* Content composition: 5% of Korean recommended amount
*함량조성: 한국인 권장량의 5%* Content composition: 5% of Korean recommended amount
실시예 2: Example 2 :
분리유단백 또는 분리유단백 가수분해물 3.3g, 해바라기유 5.0g, 중쇄중성지방 1.3g, 글리세린 지방산에스테르 0.4g 및 하기 표 6의 무기질 혼합분말 0.7753g을 정제수 43.8106g에 균일하게 혼합 분산시키고, 150㎏/㎠ 내지 450㎏/㎠의 고압으로 균질화하였다. 여기에, 덱스트린 43.6g, 정백당 1.5g, 하기 표 7의 비타민 혼합분말 0.0141g 및 향료 0.3g 가하여 전체중량을 100g으로 한 다음, 10 내지 20분간 재차 혼합하였다. 이어, 80℃ 내지 95℃의 온도로 충진한 다음, 121℃ 내지 140℃에서 30초 내지 15분간 고온 멸균처리하여 액상의 영양조성물을 제조하였다.3.3g separated milk protein or separated milk protein hydrolyzate, 5.0g sunflower oil, 1.3g medium chain neutral fat, 0.4g glycerin fatty acid ester and 0.7753g of mineral mixed powder of Table 6 below were mixed and dispersed uniformly in 43.8106g of purified water, 150kg / Homogenized at a high pressure of 2 cm 2 to 450 kg / cm 2. To this, 43.6 g of dextrin, 1.5 g of white sugar, 0.0141 g of vitamin mixed powder and 0.3 g of fragrance of Table 7 were added to make the total weight 100 g, and then mixed again for 10 to 20 minutes. Subsequently, the mixture was filled at a temperature of 80 ° C. to 95 ° C., followed by high temperature sterilization at 121 ° C. to 140 ° C. for 30 seconds to 15 minutes, thereby preparing a liquid nutrition composition.
*함량조성: 한국인 권장량의 10%* Content Composition: 10% of the recommended amount of Koreans
*함량조성: 한국인 권장량의 10%* Content Composition: 10% of the recommended amount of Koreans
실시예 3: Example 3 :
분리유단백 또는 분리유단백 가수분해물 2.7g, 해바라기유 5.2g, 중쇄중성지방 1.3g, 글리세린 지방산에스테르 0.5g, 및 하기 표 8의 무기질 혼합분말 1.163g을 정제수 44.0158g에 균일하게 혼합 분산시키고, 150㎏/㎠ 내지 450㎏/㎠의 고압으로 균질화하였다. 여기에, 덱스트린 43.2g, 정백당 1.5g, 하기 표 9의 비타민 혼합분말 0.0212g 및 향료 0.4g을 가하여 전체중량을 100g으로 한 다음, 10 내지 20분간 재차 혼합하였다. 이어, 80℃ 내지 90℃의 온도로 충진한 다음, 121℃ 내지 140℃에서 30초 내지 15분간 고온 멸균처리하여 액상의 영양조성물을 제조하였다.2.7 g of isolated milk protein or hydrolyzed milk protein, 5.2 g of sunflower oil, 1.3 g of medium chain neutral fat, 0.5 g of glycerin fatty acid ester, and 1.163 g of the inorganic mixed powder of Table 8 were uniformly mixed and dispersed in 44.0158 g of purified water, and 150 kg. Homogenized at a high pressure of / cm 2 to 450kg / cm 2. 43.2 g of dextrin, 1.5 g per white, 0.0212 g of vitamin mixed powder of Table 9 and 0.4 g of fragrance were added thereto to make the total weight 100 g, and then mixed again for 10 to 20 minutes. Subsequently, the mixture was filled at a temperature of 80 ° C. to 90 ° C., and then sterilized at 121 ° C. to 140 ° C. for 30 seconds to 15 minutes to prepare a liquid nutrition composition.
*함량조성: 한국인 권장량의 15%* Content Composition: 15% of Korean recommended
*함량조성: 한국인 권장량의 5%* Content composition: 5% of Korean recommended amount
실시예 4: Example 4 :
분리유단백 또는 분리유단백 가수분해물 7.1g, 해바라기유 3.4g, 중쇄중성지방 1.3g, 글리세린 지방산에스테르 0.3g, 및 하기 표 8의 무기질 혼합분말 0.3127g을 정제수 41.9802g에 균일하게 혼합 분산시키고, 150㎏/㎠ 내지 450㎏/㎠의 고압으로 균질화하였다. 여기에 덱스트린 43.9g, 정백당 1.5g, 상기 표 5의 비타민 혼합분말 0.0071g 및 향료 0.2g을 가하여 전체중량을 100g으로 한 다음, 10 내지 20분간 재차 혼합하였다. 이어, 80℃ 내지 95℃의 온도로 충진한 다음, 121℃ 내지 140℃에서 30초 내지 15분간 고온 멸균처리하여 액상의 영양조성물을 제조하였다.7.1 g of separated milk protein or separated milk protein hydrolyzate, 3.4 g of sunflower oil, 1.3 g of medium chain neutral fat, 0.3 g of glycerin fatty acid ester, and 0.3127 g of inorganic mixed powder of Table 8 were uniformly mixed and dispersed in 41.9802 g of purified water, and 150 kg. Homogenized at a high pressure of / cm 2 to 450kg / cm 2. 43.9g of dextrin, 1.5g per white, 0.0071g of vitamin mixed powder of Table 5 and 0.2g of flavor were added to make the total weight 100g, and then mixed again for 10 to 20 minutes. Subsequently, the mixture was filled at a temperature of 80 ° C. to 95 ° C., followed by high temperature sterilization at 121 ° C. to 140 ° C. for 30 seconds to 15 minutes, thereby preparing a liquid nutrition composition.
*함량조성: 한국인 권장량의 5%* Content composition: 5% of Korean recommended amount
실시예 5: Example 5 :
분리유단백 또는 분리유단백 가수분해물 6.5g, 해바라기유 5.0g, 중쇄중성지방 1.3g, 글리세린 지방산에스테르 0.4g, 및 하기 표 11의 무기질 혼합분말 0.6253g을 정제수 45.1106g에 균일하게 혼합 분산시키고, 150㎏/㎠ 내지 450㎏/㎠의 고압으로 균질화하였다. 여기에 덱스트린 39.3g, 정백당 1.45g, 상기 표 7의 비타민 혼합분말 0.0141g 및 향료 0.3g을 가하여 전체중량을 100g으로 한 다음, 10 내지 20분간 재차 혼합하였다. 이어, 80℃ 내지 95℃의 온도로 충진한 다음, 121℃ 내지 140℃에서 30초 내지 15분간 고온 멸균처리하여 액상의 영양조성물을 제조하였다.6.5 g of the separated milk protein or the separated milk protein hydrolyzate, 5.0 g of sunflower oil, 1.3 g of medium chain neutral fat, 0.4 g of glycerin fatty acid ester, and 0.6253 g of the inorganic mixed powder of Table 11 were uniformly mixed and dispersed in 45.1106 g of purified water, and 150 kg. Homogenized at a high pressure of / cm 2 to 450kg / cm 2. 39.3 g of dextrin, 1.45 g of white sugar, 0.0141 g of vitamin mixed powder of Table 7 and 0.3 g of fragrance were added thereto to make the total weight 100 g, and then mixed again for 10 to 20 minutes. Subsequently, the mixture was filled at a temperature of 80 ° C. to 95 ° C., followed by high temperature sterilization at 121 ° C. to 140 ° C. for 30 seconds to 15 minutes, thereby preparing a liquid nutrition composition.
*함량조성: 한국인 권장량의 10%* Content Composition: 10% of the recommended amount of Koreans
실시예 6: Example 6 :
분리유단백 또는 분리유단백 가수분해물 7.6g, 해바라기유 5.2g, 중쇄중성지방 1.3g, 글리세린 지방산에스테르 0.5g, 및 하기 표 12의 무기질 혼합분말 0.938g을 정제수 45.7408g에 균일하게 혼합 분산시키고, 150㎏/㎠ 내지 450㎏/㎠의 고압으로 균질화하였다. 여기에 덱스트린 36.8g, 정백당 1.5g, 상기 표 9의 비타민 혼합분말 0.0212g 및 향료 0.4g을 가하여 전체중량을 100g으로 한 다음, 10 내지 20분간 재차 혼합하였다. 이어, 80℃ 내지 95℃의 온도로 충진한 다음, 121℃ 내지 140℃에서 30초 내지 15분간 고온 멸균처리하여 액상의 영양조성물을 제조하였다.7.6 g of separated milk protein or separated milk protein hydrolyzate, 5.2 g of sunflower oil, 1.3 g of medium chain neutral fat, 0.5 g of glycerin fatty acid ester, and 0.938 g of the inorganic mixed powder of Table 12 were uniformly mixed and dispersed in 45.7408 g of purified water, and 150 kg. Homogenized at a high pressure of / cm 2 to 450kg / cm 2. 36.8 g of dextrin, 1.5 g of white spirit, 0.0212 g of vitamin mixed powder of Table 9 and 0.4 g of flavor were added thereto to make the total weight 100 g, and then mixed again for 10 to 20 minutes. Subsequently, the mixture was filled at a temperature of 80 ° C. to 95 ° C., followed by high temperature sterilization at 121 ° C. to 140 ° C. for 30 seconds to 15 minutes, thereby preparing a liquid nutrition composition.
*함량조성: 한국인 권장량의 15%* Content Composition: 15% of Korean recommended
실시예 7: Example 7 :
본 영양조성물의 영양효과가 신장병 환자에서 각종 영양상태를 향상시킬 수 있는가를 임상학적으로 검토하고자, 6개월 이상 복막투석을 시행받고 있는 환자중 영양불량 상태인 환자 15명을 대상으로, 1일 400∼800kcal와 12∼24g의 단백질을 공급하는 본 발명의 액상 영양조성물을 3개월 동안 경구투여하면서, 영양상태를 반영하는 지표인 혈청 생화학적 지표, 주관적, 영양상태 평가(subjective global assessment, 이하 'SGA'로 약함), 및 인체계측치를 조사하여, 투여 전후 영양상태를 펑가하고, 11명의 대조군과 비교 분석하였다. 그 결과, 3개월 후 영양조성물 투여군에서 평균체중, 이상체중 %(% IBW), 체질량지수(BMI), 체지방 분율, 총근육량 및 상완근육둘레 등의 인체계측기가 통계학적으로 유의있게 증가한 것이 확인되어, 본 발명의 액상 영양조성물이 신장질환자를 위한 영양공급원으로서 적절한 것으로 판명되었다(참조: 표 13).In order to clinically examine whether the nutritional effect of this nutrient composition can improve various nutritional status in patients with nephropathy, the subjects of 15 malnourished patients who had undergone peritoneal dialysis for 6 months or more were 400 to 1 day. Serum biochemical index, subjective, subjective global assessment (SGA), which is an indicator of nutritional status, was orally administered for 3 months orally with the liquid nutritional composition of the present invention supplying 800 kcal and 12-24 g of protein. Weak), and phylogenetic measurements were performed to determine the nutritional status before and after administration and to compare with 11 controls. As a result, it was confirmed that the human body measurements such as mean weight,% abnormal body weight (% IBW), body mass index (BMI), body fat fraction, total muscle mass and circumferential muscle circumference increased significantly in the nutrient-treated group after 3 months. In addition, the liquid nutritional composition of the present invention has been found to be suitable as a nutritional source for kidney disease (Table 13).
이상에서 상세히 설명하였듯이, 본 발명의 영양조성물은 100g당 총 200㎉의 열량을 가지며, 3대 영양소(단백질, 지방, 탄수화물)의 열량비율이 단백질 4 내지 14 중량 %, 지방 22.5 내지 31.5 중량 % 및 탄수화물 62 내지 74 중량 %이고, 비타민류와 무기질류는 한국인 성인 1일 권장량의 5 내지 15 중량 %를 함유한 영양균형 특수영양식품으로서, 단순불포화지방산에 대한 다가불포화지방산의 비율(P/M)이 1이하이고, 유당을 함유하지 않는다. 투석 신장병 환자를 대상으로 한 임상연구 결과, 본 발명의 영양조성물을 이용한 3개월 정도의 경구 영양보충은 환자의 순응도가 높았으며, 인체계측학적 영양상태 지표를 호전시키는 결과를 가져왔다. 따라서, 본 발명의 신장병 환자용 액상 영양조성물은 기존의 병원이나 가정에서 이루어지던 신장병 환자용 식이에 비하여, 보다 간편하고 효과적으로 신장병 환자에게 영양을 공급할 수 있는 새로운 영양물질로 사용될 수 있다.As described in detail above, the nutritional composition of the present invention has a total calories of 200㎉ per 100g, the caloric ratio of the three major nutrients (proteins, fats, carbohydrates) is 4 to 14% by weight protein, 22.5 to 31.5% by weight fat and Carbohydrate 62 to 74% by weight, vitamins and minerals are nutritional balance special nutrition products containing 5 to 15% by weight of the daily recommended amount of Korean adults, the ratio of polyunsaturated fatty acid to monounsaturated fatty acid (P / M) It is 1 or less and does not contain lactose. As a result of clinical studies in dialysis kidney patients, oral nutrition supplement for 3 months using the nutritional composition of the present invention had high compliance of patients and resulted in improvement of anthropometric nutritional status indicators. Therefore, the liquid nutritional composition for kidney disease patients of the present invention can be used as a new nutritional substance that can more easily and effectively provide nutrition to kidney disease patients, compared to the diet for kidney disease patients made in existing hospitals or homes.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020000002937A KR100266799B1 (en) | 1998-02-03 | 2000-01-21 | Nutritional formula for patients with renal disease and process for preparing the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019980002990A KR100266798B1 (en) | 1998-02-03 | 1998-02-03 | A nutritional product for persons receiving renal dialysis |
KR1020000002937A KR100266799B1 (en) | 1998-02-03 | 2000-01-21 | Nutritional formula for patients with renal disease and process for preparing the same |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019980002990A Division KR100266798B1 (en) | 1998-02-03 | 1998-02-03 | A nutritional product for persons receiving renal dialysis |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20000030024A KR20000030024A (en) | 2000-05-25 |
KR100266799B1 true KR100266799B1 (en) | 2000-09-15 |
Family
ID=19532425
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019980002990A KR100266798B1 (en) | 1998-02-03 | 1998-02-03 | A nutritional product for persons receiving renal dialysis |
KR1020000002937A KR100266799B1 (en) | 1998-02-03 | 2000-01-21 | Nutritional formula for patients with renal disease and process for preparing the same |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019980002990A KR100266798B1 (en) | 1998-02-03 | 1998-02-03 | A nutritional product for persons receiving renal dialysis |
Country Status (1)
Country | Link |
---|---|
KR (2) | KR100266798B1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100515923B1 (en) * | 2002-10-22 | 2005-09-21 | 이환업 | The bio conjugated proteins is process of produce |
KR20040035504A (en) * | 2002-10-22 | 2004-04-29 | 이환업 | The bio conjugated proteins is process of produce by detoxication antioxidant function and control of smoking function |
CN108308608A (en) * | 2018-03-15 | 2018-07-24 | 北京康爱营养科技股份有限公司 | A kind of full nutrient formulation liquid suitable for haemodialysis nephrotic |
-
1998
- 1998-02-03 KR KR1019980002990A patent/KR100266798B1/en active IP Right Grant
-
2000
- 2000-01-21 KR KR1020000002937A patent/KR100266799B1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR20000030024A (en) | 2000-05-25 |
KR19990069013A (en) | 1999-09-06 |
KR100266798B1 (en) | 2000-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2054268C (en) | Nutritional composition | |
EP0721742B1 (en) | Nutrition for elderly patients | |
CN1104855C (en) | Composition and its use as food supplement or for lowering lipids in serum | |
RU2289955C2 (en) | Nutritional formula for prophylaxis and treatment of immune conditions | |
US4921877A (en) | Liquid nutritional formula for glucose intolerance | |
TWI332399B (en) | Nutritional composition for controlling blood sugar level | |
DE60119919T2 (en) | FREE AMINOIC COMPOSITION | |
JP4846900B2 (en) | Nutritional products for patients with renal failure | |
US4690820A (en) | High-caloric, high-fat dietary formula | |
US5340603A (en) | Nutritional product for human infants having chronic lung disease | |
JP2599400B2 (en) | Formulated liquid nutritional composition for glucose intolerant patients | |
AU2002221860A1 (en) | Nutritional composition for an immune condition | |
KR20070054739A (en) | Total enteral nutritious composition | |
EP1401293A1 (en) | Calorically dense liquid oral supplement | |
JPS6236645B2 (en) | ||
CN107048137A (en) | It is a kind of suitable for low-phosphorus whey albumen powder of Patients with Chronic Renal Disease and preparation method thereof | |
EP1351584A2 (en) | Nutritional composition for a bone condition | |
KR100266799B1 (en) | Nutritional formula for patients with renal disease and process for preparing the same | |
JP2001316278A (en) | Liquid enteral nutrition composition | |
JP3589807B2 (en) | Nutritional composition of liquid preparation adapted to each symptom of kidney disease patients | |
CN115104731B (en) | Nutritional composition and food comprising said nutritional composition | |
MERRILL | Nutrition in chronic renal failure | |
Rubini et al. | Dietary management of end-stage uremia. | |
Rutishauser et al. | Toasted full-fat soya flour in treatment of kwashiorkor. | |
AU2263800A (en) | Nourishing products enriched with nucleosides and/or nucleotides for infants and adults and processes for their preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130118 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20140625 Year of fee payment: 15 |
|
FPAY | Annual fee payment |
Payment date: 20150624 Year of fee payment: 16 |
|
FPAY | Annual fee payment |
Payment date: 20160627 Year of fee payment: 17 |
|
FPAY | Annual fee payment |
Payment date: 20170622 Year of fee payment: 18 |